Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, Anti-Abeta Ab2, in nonclinical species

Pharmaceutical Research

Volumn 28, Issue 7, 2011, Pages 1696-1706

  Vugmeyster, Yulia ^a   Szklut, Pam ^a   Wensel, David ^a   Ross, John ^a   Xu, Xin ^a   Awwad, Michel ^a   Gill, Davinder ^a   Tchistiakov, Lioudmila ^a   Warner, Garvin ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; anti Abeta antibody; fibrinogen; human PK prediction; pharmacokinetics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; FIBRINOGEN; MONOCLONAL ANTIBODY AB2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 79959872712     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0405-x     Document Type: Article

References (33)

1. F Bard C Cannon R Barbour RL Burke D Games H Grajeda, et al. 2000 Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 916 919 10932230 10.1038/78682 1:CAS:528:DC%2BD3cXlsFamtL4%3D (Pubitemid 30644751)
2. D Games F Bard H Grajeda T Guido K Khan F Soriano, et al. 2000 Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42 Ann N Y Acad Sci 920 274 284 11193164 10.1111/j.1749-6632.2000.tb06936.x 1:CAS:528:DC%2BD3MXotlahsg%3D%3D (Pubitemid 32056582)
3. CA Lemere M Maier L Jiang Y Peng TJ Seabrook 2006 Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans Rejuvenation Res 9 77 84 16608400 10.1089/rej.2006.9.77 1:CAS:528:DC%2BD28Xjtlalsb4%3D
4. GA Jicha 2009 Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? Expert Opin Biol Ther 9 481 491 19344284 10.1517/14712590902828285 1:CAS:528:DC%2BD1MXktFCjsro%3D
5. DM Wilcockand CA Colton 2008 Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials J Alzheimers Dis 15 555 569
6. L Holcomb MN Gordon E McGowan X Yu S Benkovic P Jantzen, et al. 1998 Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes Nat Med 4 97 100 9427614 10.1038/nm0198-097 1:CAS:528:DyaK1cXjt1OhsA%3D%3D (Pubitemid 28133087)
7. MC Irizarry F Soriano M McNamara KJ Page D Schenk D Games, et al. 1997 Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse J Neurosci 17 7053 7059 9278541 1:CAS:528:DyaK2sXmtVKmurg%3D (Pubitemid 27427884)
8. T Kawarabayashi LH Younkin TC Saido M Shoji KH Ashe SG Younkin 2001 Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease J Neurosci 21 372 381 11160418 1:CAS:528:DC%2BD3MXnslCguw%3D%3D (Pubitemid 32107428)
9. JS Jacobsen CC Wu JM Redwine TA Comery R Arias M Bowlby, et al. 2006 Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 103 5161 5166 16549764 10.1073/pnas.0600948103 1:CAS:528:DC%2BD28XjsVGlt7w%3D
10. TE Golde P Das Y Levites 2009 Quantitative and mechanistic studies of abeta immunotherapy CNS Neurol Disord Drug Targets 8 31 49 19275635 10.2174/187152709787601830 1:CAS:528:DC%2BD1MXktlanurw%3D
11. Y Levites LA Smithson RW Price RS Dakin B Yuan MR Sierks, et al. 2006 Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models Faseb J 20 2576 2578 17068112 10.1096/fj.06-6463fje 1:CAS:528:DC%2BD28Xht1yls7nF (Pubitemid 44953785)
12. RC Dodel H Hampel Y Du 2003 Immunotherapy for Alzheimer's disease Lancet Neurol 2 215 220 12849209 10.1016/S1474-4422(03)00349-1 1:CAS:528: DC%2BD3sXkvVKqt78%3D (Pubitemid 37443308)
13. DL Brody DM Holtzman 2008 Active and passive immunotherapy for neurodegenerative disorders Annu Rev Neurosci 31 175 193 18352830 10.1146/annurev.neuro.31.060407.125529 1:CAS:528:DC%2BD1cXpt12nsrs%3D
14. MN Gaugler J Tracy K Kuhnle A Crameri RM Nitsch MH Mohajeri 2005 Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo FEBS Lett 579 753 756 15670841 10.1016/j.febslet.2005.01.002 1:CAS:528:DC%2BD2MXmsVGrsw%3D%3D
15. RA Karlnoski A Rosenthal J Alamed V Ronan MN Gordon PE Gottschall, et al. 2008 Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice J Neuroimmune Pharmacol 3 187 197 18607758 10.1007/s11481-008-9114-6
16. Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X. Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci. 99:1028-45.
17. C Janus D Westaway 2001 Transgenic mouse models of Alzheimer's disease Physiol Behav 73 873 886 11566220 10.1016/S0031-9384(01)00524-8 1:CAS:528:DC%2BD3MXmvVyku7k%3D (Pubitemid 32885575)
18. P Lichtlen MH Mohajeri 2008 Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools J Neurochem 104 859 874 17986215 10.1111/j.1471-4159.2007.05064.x 1:CAS:528: DC%2BD1cXivFaksrc%3D (Pubitemid 351143651)
19. P Yu G Oberto 2000 Alzheimer's disease: transgenic mouse models and drug assessment Pharmacol Res 42 107 114 10887038 10.1006/phrs.2000.0670 (Pubitemid 30658938)
20. CB Davis EM Garver DC Kwok JJ Urbanski 1996 Disposition of metabolically radiolabeled CE9.1-a macaque-human chimeric anti-human CD4 monoclonal antibody-in transgenic mice bearing human CD4 Drug metabolism and disposition: the biological fate of chemicals 24 1032 1037 1:CAS:528:DyaK28XlvV2itL4%3D (Pubitemid 26314558)
21. WS Putnam J Li J Haggstrom C Ng S Kadkhodayan-Fischer M Cheu, et al. 2008 Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody The AAPS Journal 10 425 430 18686041 10.1208/s12248-008-9045-4 1:CAS:528:DC%2BD1cXhtlOgsbnM
22. J Ghiso M Shayo M Calero D Ng Y Tomidokoro S Gandy, et al. 2004 Systemic catabolism of Alzheimer's Abeta40 and Abeta42 J Biol Chem 279 45897 45908 15322125 10.1074/jbc.M407668200 1:CAS:528:DC%2BD2cXovVCntrk%3D (Pubitemid 39491582)
23. A Amris CJ Amris 1964 Turnover and distribution of 131-iodine-labelled human fibrinogen Thromb Diath Haemorrh 11 404 422 14191721 1:STN:280: DyaF2c7kvFOnug%3D%3D
24. S Areekul K Devakul T Chongsuphajaisiddhi P Vivatanasesth K Kanakakorn R Kasemsuth 1971 Metabolism of 131 I-labelled fibrinogen in monkeys infected with Plasmodium coatneyi Southeast Asian J Trop Med Public Health 2 455 461 5004139 1:STN:280:DyaE387ksVOgtg%3D%3D
25. AK Moza RP Sapru 1982 Turnover of radio-iodinated and biosynthetically labelled fibrinogen in rhesus monkeys Indian J Med Res 76 609 617 7152569 1:CAS:528:DyaL3sXivF2l (Pubitemid 13111776)
26. C Negrier C Rothschild J Goudemand JY Borg S Claeyssens MC Alessi, et al. 2008 Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate J Thromb Haemost 6 1494 1499 18627444 10.1111/j.1538-7836.2008. 03076.x 1:CAS:528:DC%2BD1cXhtFyqur%2FN
27. GN Tytgat D Collen M Verstraete 1971 Metabolism of fibrinogen in cirrhosis of the liver J Clin Invest 50 1690 1701 5163179 10.1172/JCI106658 1:CAS:528:DyaE3MXkvFKmu7Y%3D
28. Bonfanti U, Lamparelli D, Colombo P, Bernardi C. Hematology and serum chemistry parameters in juvenile cynomolgus monkeys (Macaca fascicularis) of Mauritius origin: comparison between purpose-bred and captured animals. J Med Primatol. 2009.
29. RA Stern JQ Trojanowski VM Lee 1990 Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood FEBS Lett 264 43 47 1692541 10.1016/0014-5793(90)80760-G 1:CAS:528:DyaK3cXkt1Wksbw%3D (Pubitemid 20139801)
30. DL Merkle CH Cheng FJ Castellino BA Chibber 1996 Modulation of fibrin assembly and polymerization by the beta-amyloid of Alzheimer's disease Blood Coagul Fibrinolysis 7 650 658 8899155 10.1097/00001721-199609000-00011 1:CAS:528:DyaK28XntVentLo%3D (Pubitemid 26370224)
31. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron. 66:695-709.
32. J Ghiso A Rostagno JE Gardella L Liem PD Gorevic B Frangione 1992 A 109-amino-acid C-terminal fragment of Alzheimer's-disease amyloid precursor protein contains a sequence, -RHDS-, that promotes cell adhesion Biochem J 288 Pt 3 1053 1059 1281980 1:CAS:528:DyaK3sXltVCi (Pubitemid 23031794)
33. TA Springer J Zhu T Xiao 2008 Structural basis for distinctive recognition of fibrinogen gamma C peptide by the platelet integrin alphaIIbbeta3 J Cell Biol 182 791 800 18710925 10.1083/jcb.200801146 1:CAS:528: DC%2BD1cXhtV2rur3I